U.K.'s NICE Rejects Lucentis For Macular Edema; Avastin Remains Poised For Appraisal
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE's preliminary rejection of Lucentis for macular edema paves the way for cheaper Avastin to swallow up most of the U.K. market.